MAKO Medical Exceeds 10 Million COVID-19 Tests – GlobeNewswire

Share Article

| Source: MAKO Medical MAKO Medical
Raleigh, North Carolina, UNITED STATES
Raleigh, North Carolina, Jan. 10, 2022 (GLOBE NEWSWIRE) —  MAKO Medical Laboratories, a national reference laboratory and leader in COVID-19 testing, today announced that it has surpassed another major milestone by processing its 10 millionth COVID-19 test.
“With the recent surge in the Omicron variant, our MAKO Medical team has seen a significant spike in tests and we have continued to scale up to meet this increasing demand,” said Josh Arant, Chief Operating Officer, MAKO Medical. “This latest milestone of 10 million tests underscores the effort we have put in to deliver rapid, reliable test results across the country and assist public health authorities as they monitor the spread of the virus.”
Founded in 2014, MAKO Medical is a College of American Pathologists (CAP) accredited laboratory that operates more than 70,000 square feet of laboratory space across two North Carolina facilities, one in Henderson and one in Raleigh.  The Henderson facility was expanded in 2020 in response to COVID-19, increasing the lab’s capacity from 50,000 COVID-19 tests per day to over 150,000 tests per day.
Since April 2020, MAKO Medical has processed more than 10 million COVID-19 tests utilizing RT-PCR technology and industry-leading testing assays, including the Applied Biosystems TaqPath COVID-19 Combo Assay. Currently, the MAKO team processes more than 60,000 COVID-19 samples per day from over 40 states.
Last year, MAKO Medical formed a comprehensive partnership with the CDC to provide next-generation sequencing of SARS-CoV-2. Since January 2021, MAKO has utilized sequencing processes to analyze a group of more than 5,000 samples for sequencing per week from tests conducted across more than 40 states. To date, these efforts have identified the occurrence of multiple variants of the SARS-CoV-2 virus, including the B.1.1.7, B.1.351, B.1.429, B.1.617.2 and now the B.1.1.529 variants.
MAKO Medical also partnered with leading life sciences company Thermo Fisher Scientific to leverage its high-capacity sequencing platforms, which provide high-quality sequencing data. Thermo Fisher confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit*, and TaqPath COVID-19 CE-IVD RT-PCR Kit*, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results.
As Arant explained, this technology allows MAKO Medical to single out samples that contain characteristics specific to the novel Omicron variant.
“The qPCR assay our MAKO Medical team deploys checks for all three targets in a COVID-19 positive test result, the N gene, S gene, and ORF1ab,” said Arant.  “This is important because unlike the delta variant, which produces a signal for all three targets, early indication shows that the omicron variant is unique in that it will only produce a signal for the N gene and the ORF1ab gene. The TaqPath assay can be used as a proxy for the Omicron variant.”
Since the emergence of COVID-19, scientists have monitored the surge of variants and mutations of the virus. While a natural process for any virus, mutations of SARS-CoV-2 represent an outsized risk due to the impact that they may have on virus containment and vaccine efficacy.
MAKO’s team also provides turnkey K-12 COVID-19 testing in several states and has begun providing onsite workplace and large gathering COVID-19 testing with mobile units that can be dispatched to rapidly serve group needs.  To learn more about workplace and large gathering COVID-19 testing visit To learn more about K-12 COVID-19 testing visit
Company Highlights:

 About MAKO Medical
Founded in 2014, MAKO Medical is a diagnostics partner for businesses, physicians, urgent care facilities, and hospitals around the United States. MAKO Medical has recruited chemists and scientists to provide industry-leading innovation. MAKO Medical Laboratories’ methods and assays are validated for reproducibility, precision, and accuracy. MAKO Medical invests heavily in state-of-the-art instrumentation and technology. To learn more, visit


You might also like

Surviving 2nd wave of corona

Surviving The 2nd Wave of Corona

‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort